Research Article
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma
Table 4
Univariate analysis of factors regarding tumor progression and death using TMA-3.
| Variable Categorization | Death | Tumor progression | | events | | | events | |
| Advance melanoma patients | | | | | | | Age | | | | | | | 60 years | 12 | 7 | 0.152 | 12 | 11 | 0.163 | 60 years | 22 | 14 | | 22 | 18 | | Initial tumor stage | | | | | | | pT1 | 2 | 1 | 0.690 | 2 | 2 | 0.016 | pT2 | 1 | 1 | | 1 | 1 | | pT3 | 13 | 9 | | 13 | 11 | | pT4 | 9 | 6 | | 9 | 6 | | Melanoma in situ | 1 | 0 | | 1 | 1 | | Initial regional lymph node status | | | | | | | pN0 | 11 | 6 | 0.980 | 11 | 9 | 0.894 | pN1 | 9 | 8 | | 9 | 8 | | pN2 | 6 | 4 | | 6 | 5 | | pN3 | 2 | 1 | | 2 | 1 | | Study therapy | | | | | | | A: trofosfamide | 12 | 10 | 0.570 | 12 | 10 | 0.898 | B: trofosfamide + rofecoxib + pioglitazone | 23 | 12 | | 23 | 20 | | CRP | | | | | | | normal or decrease or increase | 14 | 9 | 0.115 | 14 | 11 | 0.128 | decrease | 10 | 10 | | 10 | 10 | | Cytoplasmic COX2 IHC | | | | | | | score 0 to 1+ | 14 | 10 | 0.505 | 14 | 13 | 0.338 | score 2+ to 3+ | 21 | 12 | | 21 | 17 | | Nuclear PPARG IHC | | | | | | | score 0 | 22 | 15 | 0.179 | 22 | 21 | 0.044 | score 1+ to 3+ | 13 | 7 | | 13 | 9 | |
|
|
og-rank test (two-sided).
|